Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

238 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Lindmo T, et al. Among authors: boven e. J Immunol Methods. 1984 Aug 3;72(1):77-89. doi: 10.1016/0022-1759(84)90435-6. J Immunol Methods. 1984. PMID: 6086763
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens.
Haisma HJ, Pinedo HM, Silva CA, Boven E. Haisma HJ, et al. Among authors: boven e. J Immunol Methods. 1992 Sep 18;154(1):55-60. doi: 10.1016/0022-1759(92)90212-c. J Immunol Methods. 1992. PMID: 1401943
Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody.
Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA Jr. Lindmo T, et al. Among authors: boven e. Cancer Res. 1985 Oct;45(10):5080-7. Cancer Res. 1985. PMID: 4027987
Monoclonal antibodies in cancer treatment: where do we stand after 10 years?
Boven E, Pinedo HM. Boven E, et al. Radiother Oncol. 1986 Feb;5(2):109-17. doi: 10.1016/s0167-8140(86)80165-7. Radiother Oncol. 1986. PMID: 3517970 Review.
Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Molthoff CF, Buist MR, Kenemans P, Pinedo HM, Boven E. Molthoff CF, et al. Among authors: boven e. J Nucl Med. 1992 Nov;33(11):2000-5. J Nucl Med. 1992. PMID: 1432162
Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: boven e. Int J Cancer. 2001 Feb 15;91(4):550-4. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1075>3.0.co;2-l. Int J Cancer. 2001. PMID: 11251980
CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells.
Fontijn D, Duyndam MC, van Berkel MP, Yuana Y, Shapiro LH, Pinedo HM, Broxterman HJ, Boven E. Fontijn D, et al. Among authors: boven e. Br J Cancer. 2006 Jun 5;94(11):1627-36. doi: 10.1038/sj.bjc.6603157. Br J Cancer. 2006. PMID: 16685268 Free PMC article.
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Kievit E, Pinedo HM, Schl├╝per HM, Haisma HJ, Boven E. Kievit E, et al. Among authors: boven e. Int J Cancer. 1997 Apr 10;71(2):237-45. doi: 10.1002/(sici)1097-0215(19970410)71:2<237::aid-ijc19>3.0.co;2-e. Int J Cancer. 1997. PMID: 9139849
Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.
Houba PH, Boven E, Haisma HJ. Houba PH, et al. Among authors: boven e. Bioconjug Chem. 1996 Sep-Oct;7(5):606-11. doi: 10.1021/bc960055j. Bioconjug Chem. 1996. PMID: 8889024
Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM, Boven E. Haisma HJ, et al. Among authors: boven e. Blood. 1998 Jul 1;92(1):184-90. Blood. 1998. PMID: 9639515
238 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback